| Date | Title | Description |
| 13.08.2025 | Jocasta Neuroscience: $35 Million Series A Raised For Advancing Longevity Protein Program | Jocasta Neuroscience is a company focused on improving longevity. Its main product is a special formulation of the protein alpha-Klotho, which may help treat cognitive issues linked to neurodegenerative diseases. The company recently raised... |
| 20.05.2025 | Sam Altman-Backed Startup Aims to Add 10 Years to Human Life Through Stem Cell Tech | OpenAI’s Sam Altman has poured millions into the longevity-focused Retro Biosciences. Sean Gallup/Getty Images
The average American can expect to live about 77 years, according to the Centers for Disease Control and Prevention. Retro Biosci... |
| 21.06.2024 | Ascentage Pharma Announces Closing of US$75 Million Equity Investment by Takeda | ROCKVILLE, Md. and SUZHOU, China, June 21, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced ... |
| 18.06.2024 | Live from EHA 2024 | Ascentage Pharma Releases Updated Data of Lisaftoclax in Patients with R/R MM and AL Amyloidosis Highlighting Marked Improvement in ORR | SUZHOU, China and ROCKVILLE, Md., June 18, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced ... |
| 11.06.2024 | Global Registrational Phase III Study of Olverembatinib for the Treatment of Patients with SDH-Deficient GIST Approved by the China CDE | SUZHOU, China, and ROCKVILLE, Md., June 11, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced... |
| 05.06.2024 | Live from ASCO 2024 | Oral Report Released Latest Data of Olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3% | SUZHOU, China and ROCKVILLE, Md., June 5, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced t... |
| 05.06.2024 | Live from ASCO 2024 | Ascentage Pharma Releases Updated Data Showing Promising Efficacy and Safety of Lisaftoclax in Patients with WM | SUZHOU, China, and ROCKVILLE, Md., June 5, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced ... |
| 04.06.2024 | Live from ASCO 2024 | Updated Data of Bcl-2 Inhibitor Lisaftoclax Combined with Azacitidine in Patients with AML Demonstrate Promising Efficacy and Manageable Safety | SUZHOU, China and ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced t... |
| 16.05.2024 | EHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress | SUZHOU, China and ROCKVILLE, Md., May 16, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced t... |
| 25.04.2024 | ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest Data of Olverembatinib in SDH-Deficient GIST | SUZHOU, China and ROCKVILLE, Md., April 25, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced... |
| 08.04.2024 | AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting | ROCKVILLE, Md. and SUZHOU, China, April 8, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, age-related diseases, and chronic hepatitis B (CHB), announced ... |
| 06.03.2024 | AACR 2024 | Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting | ROCKVILLE, Md. and SUZHOU, China, March 6, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, age-related diseases, and chronic hepatitis B (CHB), announced ... |
| 30.05.2023 | Люди не могут жить вечно, но мы даже близко не подошли к пределу продолжительности жизни | На протяжении тысячелетий люди пытались продлить свою жизнь как можно сильнее. Мы пробовали замораживание, голодание и разные растительные средства.
Недавно такие миллиардеры, как Ларри Пейдж, Марк Цукерберг и Джефф Безос, вложили огромные ... |
| 20.04.2023 | Humans can't live forever, but we haven't even come close to the limit for how long our bodies could last | Millions of dollars are going toward companies worldwide looking to lengthen the human lifespan. invincible_bulldog / Getty Images
Redeem now
Researchers estimate that the human body may not be capable of living more than 150 years.
But doz... |
| 19.08.2022 | Norwegian biotech to enact layoffs; Unity halves its public offering | Norwegian drug developer PCI Biotech said it couldn’t secure the funds to bankroll a Phase II cancer trial.
The Oslo biotech put out word Thursday afternoon that it couldn’t find a “feasible way forward” in funding a Phase II... |
| 12.08.2022 | Unity finds itself with a finite amount of cash as new data provide a ray of hope for investors | It has not been an easy road for the anti-aging startup Unity Biotechnology. From staff cuts to a lead program loss, the company has run into several obstacles on its journey, but their latest news points to both the peril... |
| 12.08.2022 | Senate Finance chair continues his investigation into pharma taxes with requests for Amgen | Pfizer was first to the finish line for the next-gen pneumococcal vaccine in adults, but Merck beat its rival with a jab for children in June.
Now, two months after Merck’s 15-valent Vaxneuvance won the FDA stamp of approval for kids, Pfize... |
| 13.07.2022 | Amazon joins Fred Hutch on clinical trial for personalized cancer vaccine — report | Amazon is partnering with the Fred Hutchinson Cancer Research Center on a Phase I trial for a cancer vaccine targeting metastatic melanoma and breast cancer.
The clinical trial is part of Amazon’s Grand Challenge, a sec... |
| 29.07.2021 | Ascentage Pharma : Announces Another Milestone Payment from Its Licensee UNITY Biotechnology, Rapidly Advancing the Clinical Development of Senolytic Drug Candidate UBX1325 | SUZHOU, China, and ROCKVILLE, Md., July 28, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today an... |
| 29.07.2021 | Ascentage Pharma Announces Another Milestone Payment from Its Licensee UNITY Biotechnology, Rapidly Advancing the Clinical Development of Senolytic Drug Candidate UBX1325 | SUZHOU, China, and ROCKVILLE, Md., July 29, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today an... |
| 28.07.2021 | Ascentage Pharma Announces Another Milestone Payment from Its Licensee UNITY Biotechnology, Rapidly Advancing the Clinical Development of Senolytic Drug Candidate UBX1325 | |
| 23.04.2021 | Longevity startup Longevica plans to launch supplements based on long-term research | A biotech company that has spent 11 years researching supplements to increase human longevity plans to launch its supplements later this year. Longevica says it has attracted a total of $13 million from investors, including Alexander Chikun... |
| 15.09.2020 | A month after losing its lead program, Unity Biotechnology cuts 30% of staff in restructuring | Unity Biotechnology’s lead anti-aging program faced the chopping block last month following a major Phase II flop. And now, 30% of its staff are next, as the company restructures to focus on ophthalmology and neurolog... |
| 28.08.2020 | Laura Deming, Frederik Groce, Amish Jani, Jessica Verrilli and Vanessa Larco are coming to Disrupt | At TechCrunch Disrupt, our Startup Battlefield competition this year looks to be fiercer than ever, judging by the applicants. That’s actually saying something, considering the game-changing brands to emerge from our stage over the years, i... |
| 17.06.2020 | CAR-T cells, better known as cancer drugs, show promise against aging in lab mice | Scientists are still trying to get CAR-T cells to work as well in solid tumors as they do in blood cancers, but the genetically engineered immune cells just might have a superpower beyond oncology. In mice, researchers reported on Wednesday... |
| 20.09.2018 | Кто инвестирует в бессмертие Статьи редакции | «Вампирский» стартап, криоконсервация и другие проекты, в которые вкладывают миллиардеры.
57 57 комментариев
9911 просмотров
Биотехнологический стартап от Google
Ещё в 1999 году футурист Рэймонд Курцвейл в своей книге «Эпоха духовных машин:... |
| 29.08.2018 | Top tech startup news stories you need to know this Wednesday, August 29 | Good morning! Here are some of the top tech startup news stories for today, Wednesday, August 29.
Andreessen Horowitz invests $102 million in Dfinity, a blockchain start-up building the “world computer.” Dfinity, a blockchain start-up buil... |
| 09.07.2018 | Hope for creaky old humans: Removing aged cells from mice can restore their youth, study finds | If creaky old humans were more like dilapidated old kitchens, rejuvenation would be as simple as replacing cracked and faded Formica with gleaming new granite. But perhaps, a booming new scientific field hypothesizes, biological renovation ... |
| 07.05.2018 | Unity Biotechnology, Inc. Announces Closing of Initial Public Offering | - |
| 23.04.2018 | Term Sheet — Monday, April 23 | IPO AVALANCHE
Good morning, Term Sheet readers.
Paid Content What you need to know about growing cyberattacks From ExtraHop
On to the news.
EYE-POPPING IPO: Is Spotify about to be one-upped? China streaming giant Tencent Music is getting re... |
| 09.04.2018 | Top 10 VCs investing in mental/behavioral health | They include Polaris Partners, .406 Ventures, Y Combinator and Khosla Ventures
Healthcare is such a massive space, one that takes up a sixth of the entire U.S. economy, that just one small piece of that pie can be extremely lucrative. Take ... |
| 20.03.2018 | Term Sheet — Tuesday, March 20 | FERRO OUT
Good morning, Term Sheet readers. Lots of news today.
Paid Content You can't secure what you can't see From ExtraHop
Some people on Twitter were skeptical about the sudden retirement, asking “What’s the rest of the story?”
Hours l... |
| 19.03.2018 | UNITY Biotechnology, Inc. Completes $55 Million Series C Financing | - |
| 19.03.2018 | Unity Biotechnology Completes $55M Series C Financing | Unity Biotechnology, Inc., a San Francisco, CA-based biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, closed a $55m Series C financing.
Backers included EcoR1 Capital Fund, 6 Dimensions Capital, Alti... |
| 30.11.2017 | Anti-aging startup ResTORbio gets $40M to fuel Phase IIb study | ResTORbio, a new company developing tech spun out of Novartis, has raised $40 million in a Series B round to speed its anti-aging program through the clinic.
The startup, which was set up earlier this year as a subsidiary ... |
| 22.08.2017 | This 23-year-old just closed her second fund — which is focused on aging — with $22 million | Laura Deming is not your typical venture capitalist. Then again, she isn’t typical in many ways.
For starters, the 23-year-old, New Zealand native was home schooled, developing along the way a love of math and physics and, perhaps most inte... |
| 20.08.2017 | Unity Biotechnology Raises Additional $35M Series B from ARCH Venture Partners | UNITY Biotechnology, Inc. a privately held biotechnology company creating therapeutics that prevent, halt, or reverse numerous diseases of aging, today announced the closing of an additional $35 million in Series B financing. This second cl... |
| 20.08.2017 | Unity Biotechnology Raises Additional $35M Series B from INVUS Opportunities | UNITY Biotechnology, Inc. a privately held biotechnology company creating therapeutics that prevent, halt, or reverse numerous diseases of aging, today announced the closing of an additional $35 million in Series B financing. This second cl... |
| 18.08.2017 | Term Sheet — Friday, August 18 | ET CETERA
Good morning from stormy NYC.
Paid Content You can't secure what you can't see From ExtraHop
That could change in California. A group called the Equal Rights Advocates has sponsored an amendment to the California Unruh Act, propos... |
| 17.08.2017 | UNITY Biotechnology Scores $35M |
SAN FRANCISCO, CA, UNITY Biotechnology today announced the closing of an additional $35 million in Series B financing.
>> Click here for more funding data on UNITY Biotechnology
>> To export UNITY Biotechnology funding data ... |
| 17.08.2017 | Unity Biotechnology Closes Additional $35M in Series B Financing | Unity Biotechnology, Inc., a San Francisco, CA-based biotechnology company creating therapeutics that prevent, halt, or reverse numerous diseases of aging, closed an additional $35m in Series B financing.
This second close of the Series B r... |
| 14.06.2017 | No, Peter Thiel is not harvesting the blood of the young | Peter Thiel has some wild ideas, but transfusing teen blood into his own body might not be his bag.
Correction below
Stories of countesses bathing in virgin blood, or vampiric nobles sucking the juice out of the young, have captured our att... |
| 03.11.2016 | The top 15 healthcare deals of 2016 | There has been $13.1 billion invested across 1,287 deals so far this year
Even as venture funding has slowed down this year, healthcare has remained one of the top spaces for companies to raise money.
In the first quarter of this year, even... |
| 31.10.2016 | Unity Biotechnology Raises $116M Series B from ARCH Venture Partners | UNITY Biotechnology, Inc., a privately held biotechnology company creating therapeutics that prevent, halt, or reverse numerous diseases of aging, today announced the closing of a $116 million Series B financing.
Coincident with the financi... |
| 31.10.2016 | Unity Biotechnology Raises $116M Series B from Venrock | UNITY Biotechnology, Inc., a privately held biotechnology company creating therapeutics that prevent, halt, or reverse numerous diseases of aging, today announced the closing of a $116 million Series B financing.
Coincident with the financi... |
| 31.10.2016 | Unity Biotechnology Raises $116M Series B from Venrock | UNITY Biotechnology, Inc., a privately held biotechnology company creating therapeutics that prevent, halt, or reverse numerous diseases of aging, today announced the closing of a $116 million Series B financing.
Coincident with the financi... |
| 31.10.2016 | Unity Biotechnology Raises $116M Series B from ARCH Venture Partners | UNITY Biotechnology, Inc., a privately held biotechnology company creating therapeutics that prevent, halt, or reverse numerous diseases of aging, today announced the closing of a $116 million Series B financing.
Coincident with the financi... |
| 28.10.2016 |
KYTHERA, Amgen Vet Takes Helm At UNITY Biotechnology After $116M Funding
| A local, Ventura County biotechnology executive, Keith Leonard, has taken the helm of UNITY Biotechnology, a heavily backed San Francisco biotech startup focused on curing diseases of aging, as a result of a big $116M funding round at the c... |
| 28.10.2016 | UNITY Biotechnology Closes $116M Series B |
SAN FRANCISCO, CA, Privately held biotechnology company announced the closing of a $116 million Series B financing.
>> Click here for more funding data on UNITY Biotechnology
>> To export UNITY Biotechnology funding data to ... |
| 28.10.2016 | Unity Biotechnology Closes $116M Series B Financing | Unity Biotechnology, Inc., a San Francisco, CA-based biotechnology company creating therapeutics aimed at preventing, halting, or reversing numerous diseases of aging, closed a $116m Series B financing.
Backers included Arch Venture Partner... |
| 28.10.2016 | Term Sheet — Friday, October 28 | SELLING OUT
Yesterday the Internet mourned the death of Twitter-owned Vine, a web product everyone apparently loved but stopped using years ago. One of the company’s co-founders, Rus Yusupov, tweeted his bitter takeaway: “Don’t sell your co... |
| 27.10.2016 | Jeff Bezos, Mayo Clinic back anti-aging startup Unity Biotechnology for $116 million | Every once in a while someone in Silicon Valley brings up the possibility of living forever, or at least a really long time, but first we’re going to need to figure out a way to enjoy all those extra years. Unity Biotechnology is a startup ... |
| - | Жизнь 3.0: Современные реалии биохакинга и перспективы на будущее | Это перевод статьи с Medium специально для vc.ru и моего Telegram-канала. Она показалась мне интересной и достойной вашего внимания. Приятного чтения!
2 2 комментария
1533 просмотров
Подготовка почвы
Здравоохранение — сложная тема. Критично... |
